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ABSTRACT 
 
Neonatal abstinence syndrome is defined by signs and symptoms of withdrawal that infants 
develop after intrauterine maternal drug exposure. All infants with documents in utero opioid 
exposure, or a high pre-test probability of exposure should have monitoring with a standard 
assessment instrument such as a Finnegan Score. A Finnegan score of >8 is highly correlated with 
opioid exposure, even in the absence of declared use during pregnancy. At least half of infants in 
most locales can be treated without the use of pharmacologic means. For this reason, symptom 
scores will drive the decision for pharmacologic therapy. However, all infants, regardless of initial 
manifestations, should be treated with non-pharmacologic approaches. Non-pharmacologic 
approaches should not be considered an alternative to drug therapy, but instead the base upon 
which all patients are treated. Those who continue to have symptoms should have addition of 
pharmacologic treatment.  
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Introduction 
Neonatal abstinence syndrome (NAS) or neonatal opioid withdrawal syndrome is defined 
by signs and symptoms of withdrawal that infants develop after intrauterine maternal drug 
exposure [1]. Following the cessation of umbilical drug transfer, presentations include mild and 
transient withdraw symptoms (nicotine, SSRIs) or toxidromes from direct drug effect (cocaine) 
[2].  In contrast, prolonged in utero exposure to opioids is associated with a more specific and often 
severe withdrawal syndrome [2]. The etiologic link has led to a proposed name of neonatal opioid 
withdrawal syndrome (NOWS) rather than the more non-specific NAS [2]. As polydrug exposure, 
particularly with concomitant benzodiazepines, is frequent and often leads to more 
symptomatology, the term NAS remains more common in clinical practice [3]. The maternal dose 
of methadone only weakly predicts severity of NAS symptoms [3]. The other clinical covariates 
of NAS severity are similarly not particularly predictive, and actionable decisions are based 
primarily on symptom presentation. Conceptually, the disease “NAS” captures a spectrum of 
severity. Imprecision of descriptions often conflate a diagnosis of NAS only with a neonatal opioid 
withdrawal that requires pharmacologic treatment. In fact, a more accurate approach is to define 
NAS as cardinal symptoms of withdrawal in the setting of known or highly suspected opioid 
exposure. NAS in whom pharmacologic therapy is used represent more severe disease. Most 
newborns will develop withdrawal symptoms within 24-48 hours after birth, however, delayed 
presentations of 5-10 days after birth are seen [4]. Severity and length of NAS might vary based 
on gestational age, type of illicit drug, and when the substance was used last. Withdrawal 
symptoms are graded using a standard instrument. The most commonly used are modifications of 
the Finnegan Score, which was developed as a research tool in the 1970’s (Figure 1 for one variant 
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known as MOTHER NAS score) [5], and once a certain Finnegan Score threshold is exceeded 
newborns are treated [6, 7]. 
 
In the last 15 years, there has been a fivefold increase in NAS, which is associated with the 
rise of opioid use during pregnancy [8]. The incidence of NAS in 2012 was estimated to be 6.0 per 
1000 live US births - a 5-fold increase since 2000. Since 2012, the incidence has continued to 
increase, with data in 2016 from 23 hospitals in the US Pediatric Health Information System 
showing an incidence of 20 per 1000 live births [9]. This puts a heavy burden on health resources 
since these newborns require prolonged medical treatment and longer hospital admission [10]. 
 
Treatment Approaches 
All infants with documents in utero opioid exposure, or a high pre-test probability of 
exposure should have monitoring with a standard assessment instrument such as a Finnegan Score. 
A Finnegan score of >8 is highly correlated with opioid exposure, even in the absence of declared 
use during pregnancy [11]. At least half of infants in most locales can be treated without the use 
of pharmacologic means. We currently do not have good predictors of which infants will go on to 
more severe disease. For this reason, symptom scores will drive the decision for pharmacologic 
therapy. However, all infants, regardless of initial manifestations, should be treated with non-
pharmacologic approaches. Non-pharmacologic approaches should not be considered an 
alternative to drug therapy, but instead the base upon which all patients are treated. Those who 
continue to have symptoms should have addition of pharmacologic treatment [Figure 1].  
 
Non-pharmacological adjunct treatments 
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Non-pharmacological management of NAS (Box 1) is the base used for all infants with in 
utero opioid exposure [12, 13]. While specific interventions vary by location, ~95% of NICUs 
offered some aspect of non-pharmacological care [12]. Many NAS symptoms cause 
overstimulation in the newborn infant and non-pharmacological adjuncts utilize environmental and 
behavioral approaches to maximize infant comfort. Mild cases of NAS (Finnegan Score <8) are 
managed solely by using non-pharmacological approaches, while more severe cases require 
treatment with medication. Common methods of non-pharmacological care include: swaddling, 
positioning, quiet and dimly lit rooms, rooming-in, skin-to-skin contact, breastfeeding, and infant 
positioning [14]. 
 
Environmental control  
Environmental control including quiet and dimly lit rooms, swaddling, positioning, and 
bed types are most commonly employed [14]. Adjusting environmental stimuli including sound 
and lights can ensure that hyper-aroused infants who experience withdrawal are not over 
stimulated. 
Swaddling, a common practice which involves tightly wrapping the infant in a blanket, has 
been shown to decrease arousal, prolong sleep, improve neuromuscular development, decrease 
physiologic distress, improve motor organization, and self-regulatory ability [15]. While no study 
has examined swaddling in infants with NAS, it is widely accepted as a safe, effective intervention. 
The positive consequences of prone position for sleep include i) fewer awakenings and increased 
time in quiet sleep, more sleep with higher arousal thresholds, lower levels of activity, enhanced 
respiratory control, and diminished heart rate variability [16]. Maichuk et al randomized newborn 
infants with NAS to prone position (n=24) or supine position (n=24) and demonstrated that the 
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mean ±SD NAS was significantly higher in supine position compared prone position 7.6 ±0.7 vs 
5.1 ±0.6 (p< 0.0001), respectively [16]. Also, supine-lying subjects had higher mean caloric intake 
(133±11 kcal/kg/24h) compared to than prone-lying infants (100±9 kcal/kg/24h) (p<0.001) [16]. 
Prone positioning decreases NAS symptoms potentially due to the cardiorespiratory and 
somatosensory effects of quieting response of prone positing [16]. Alternatively, non-oscillating 
waterbeds provide vestibular and tactile stimulation that is dependent on the neonate’s own 
activities and might decrease irritability and increases periods of sleep [17]. In addition, a non-
oscillating water bed (n=15) had significant lower NAS scores, earlier onset of consistent weight 
gain, and required up to 2mg/kg less phenobarbital compared to conventional bassinets (n=15) 
[17]. In contrast, D'Apolito et al randomized 14 infants with NAS to either a mechanical rocking 
bed or standard bed. Infants with the rocking bed therapy experienced a significant increase in 
withdrawal symptoms, poorer sleep patterns, and decreased neurobehavioral functioning on day 7 
of life in infants [mean ±SD NAS score of 10±2 compared to 8±2 (p=0.05)] [18]. These studies 
suggest that prone position if possible combined with a non-oscillating water bed provides some 
soothing effect to newborns with NAS.  
 
Feeding methods 
Breastfeeding is one of the most commonly used non-pharmacological interventions for 
infants with NAS. However, there is often confusion about the safety of breastfeeding while on 
opioid substitution therapy [19], because previous clinical guidelines proposed potential harmful 
effects and from the possibility of continued concomitant illicit drug use [20]. While drugs are 
present in breast milk of mothers on substitution therapy, concentrations are low with low oral 
bioavailability, and no documented detrimental effects on infants [20]. Several studies analyzed 
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the breast milk of mothers on methadone for substitution therapy and reported low concentration 
of methadone in the breast milk not exceed 0.1mg/kg/day, amounting to only 2% of maternal dose 
[21]. Opioid substitution therapy is not a contraindication to breastfeeding and most mothers on 
substitution therapy should be encouraged to breastfeed [21, 22, 23]. 
Breastfeeding is consistently associated with a decrease in severity of NAS. A retrospective 
chart review of 190 drug-dependent mother-infant-dyads showed reduced NAS severity within the 
first 9 days and delayed onset, 25% reduction in need for pharmacologic treatment, and up to 20-
day decrease in lengths of pharmacologic treatment, regardless of the gestation and the type of 
drug exposure when compared to formula fed [24]. Similarly, McQueen et al and Isemann et al 
also reported reduction in mean NAS scores, duration of opioid treatment, and length of hospital 
stay in breastfed infants [25, 26]. Welle-Strand et al reported a shorter mean ±SD lengths of stay 
of 28.6±19 in breastfed infants (n=95) vs. 46.7±26 (p<0.05) in formula fed infants (n=29) exposed 
to methadone, however no effect in infants exposed to buprenorphine was observed [27]. Despite 
the obvious benefits of breast milk, breastfeeding rates remain low. Wachman et al reported that 
only 24% of 276 opioid-exposed mother-infant-pairs at their baby-friendly hospital had any breast 
milk during their hospital stay with 60% of them discontinuing after an average of 6 days [28]. 
Given the documented benefit, attempts should be made to minimize potential barriers and 
increase breastfeeding rates in opioid-exposed infants. 
 
Social integration 
Parental presence might be beneficial due to rooming in or skin-to-skin contact, which 
facilitates mother and infant bonding and maternal comforting of the infant. Several studies have 
examined the effects of parental presences on NAS. Howard et al observed 86 mother-infant-dyads 
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and reported that maximum parental presence (100%) was associated with a 9 day shorter lengths 
of stay (r=-0.31) (p<0.01), an 8 day reduction of lengths of treatment (r=-0.34, p<0.001) and 1-
point decrease in mean NAS score (r=-0.35, p<0.01) [29]. Similar, Abrahams et al and Hodgson 
et al examined the effects of rooming-in in infants exposed to maternal opioids in-utero [30, 31]. 
Infants in the rooming-in cohort had much higher breastfeeding rates (63% vs. 10% in non-
rooming-in hospitals), it reduced morphine treatment (20-40% vs. 77% in non-rooming-in 
hospitals), length of hospital stay, and admission rates to Level II NICUs [30, 31]. The major 
benefit of rooming-in was the high rates of breast feeding mothers, which might have also 
contributed to some of the observed benefits [32].  
 
Acupuncture 
Acupuncture might possibly work by the release of endogenous opioids which in turn help 
restore the release of dopamine [33]. Illicit drugs can stimulate dopamine release and withdrawals 
are characterized by low levels of dopamine which can be restored by acupuncture [33]. Laser 
acupuncture is a form of non-invasive acupuncture that stimulates acupuncture points with use of 
a low level laser beam [33]. Raith et al randomized 28 preterm and term infants and reported that 
laser acupuncture combined with standard opioid treatment significantly decreases lengths of stay 
from 50 (36-66) to 35 (25-47) days in the control and acupuncture group (p=0.19), respectively 
[33]. Median (IQR) lengths of treatment was also significantly shorter with 28 (22-23) days for 
the acupuncture group compared to 39 (32-48) days for the control group (p=0.48) [33].  
Most non-pharmacological treatments (exception of rocking and outpatient therapy) are 
safe, effective and easy to be implemented as adjuncts therapies to pharmacological treatments. 
While generally low risk, such interventions do require staff time and attention for implementation, 
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and as such a systemic evaluation of specific non-pharmacological therapies would assist 
clinicians in directing time and effort toward high yield intervention while decreasing effort on 
low yield efforts.  
 
Pharmacological Treatments (Box 2) 
 The need for pharmacologic therapy is widely held to be needed for severe 
symptomatology. This is commonly linked to a specific threshold on a score (often an 8 on a 
Finnegan score) and less often explicitly linked to a goal of therapy. There is good consensus that 
there is a subset of infants that require pharmacologic therapy, but less so in defining the goals of 
care and tradeoffs associated with higher or lower threshold for treatment. Goals of pharmacologic 
therapy are to relieve infant discomfort, allow proper nutrition and development, and to foster 
parental bonding. End points in clinical trials are typically duration of therapy or length of 
hospitalization. These trial endpoints are not necessarily congruent with the aforementioned goals 
of treatment. For example, a higher threshold to start treatment and less aggressive dosing of an 
infant could lead to fewer days of treatment, but at the cost of a more irritable infant, poor feeding 
and weight gain, and parental stress. Similarly, attention is often paid to which is the best particular 
drug, without recognition that the drug resides within a treatment protocol with specific initial 
dose, up-titration schedule, maximum dose, and down titration. There have been few if any 
comparative studies that examine different regimens within a specific drug. As full agonists, 
morphine and methadone have a narrower therapeutic index than buprenorphine (partial agonist), 
but with inpatient monitored use, there are very few short-term safety issues with any of the 
commonly used opioids. With these caveats in mind, pharmacologic treatment is added when non-
pharmacologic therapies adequately control NAS withdrawal symptoms. Cochrane and a variety 
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of narrative reviews support the use of base therapy of an opioid, with the addition of an adjunctive 
therapy. The opioid dose is increased until there is adequate control of symptoms, as defined using 
a standardized symptom instrument such as the Finnegan. After a ~48 hours of stability, the dose 
is slowly weaned. For those not fully controlled with an opioid alone, adjunctive drugs are added. 
Specific regimens and doses vary between institutions, but a representative algorithm from  Royal 
Alexandra Hospital, Edmonton, Canada is presented in Figure 4. 
 
Morphine 
 Morphine is acts as a full agonist on the  opioid receptors and morphine solution is one 
of the most commonly used medications to treat NAS with ~80% of centers in the US employing 
it as primary agent [4, 34]. There is heterogeneity in dosing approaches, titration rates and maximal 
doses. The more common approach is that of weight based dosing, in which morphine is started at 
a dose of 0.07 mg/kg every 4 hours once a specific score trigger is crossed, for example if an infant 
has a Finnegan score >8 (Figure 3) [35]. An alternate approach is that the dose of morphine is not 
adjusted for weight, and instead the initial dose is based only on the Finnegan score. A high score, 
indicating severe disease, gets a high dose. The up titration is similar to the weight based approach, 
but the dose is not adjusted for size of the infant. These two approaches have not been directly 
compared to each other. Current recommendations for NAS treatment suggests oral morphine 
solution should be diluted to a concentration of 0.4 mg/mL [36]. In addition, many pharmacies 
have opted to use morphine over tincture of opium. Tincture of opium consists of opium 10mg/mL 
and requires a 25-fold dilution to achieve the recommended 0.4 mg/mL morphine.  Care must be 
taken with dilution to avoid medical errors. Oral morphine is a preferred formulation. [36]. 
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Methadone  
Methadone is a long acting mu opioid agonist, currently used in 20% of US centers. It also 
has a NMDA antagonist effects, though how this may impact the clinical efficacy relative to 
morphine, is unclear. Current evidence suggests that methadone has a modest advantage over 
morphine based upon randomized controlled trials. (Table 1) The highest quality was that of Davis, 
which was a multicenter, randomized, blinded trial of 116 term infants to either methadone or 
morphine [39]. Compared to morphine, methadone treated infants had a significantly shorter mean 
length of treatment 14.7 vs 16.6 days, and length of stay and 18.9 vs. 21.1 (p=0.02 and p=0.01), 
respectively. A caveat to this trial was the use of a bespoke hybrid weight and symptom based 
dosing regimen, which is not commonly employed. In addition, the trial used an alcohol free 
formulation of methadone that is not commercially available. This may be difficult for some 
hospital pharmacies to compound, though it is not expected that alcohol containing methadone 
solutions should have any less efficacy than the one used in the trial. There is even greater 
heterogeneity in methadone regimens than in morphine, and not a generally accepted standard 
regimen. The development of specific regimens to date has been empiric and site specific. 
However, modern pharmacometric modelled dosing regimens have demonstrated improved 
outcomes [40]. Careful linking of pharmacokinetic data, a strict treatment protocol, and clearly 
defined endpoints can generate of model that can be used to simulate new treatment regimens and 
examine subpopulations. Refinements of these model-based approaches will likely lead to further 
optimization of regimens. This approach has been piloted with methadone, but model building has 
also been explored with morphine and buprenorphine [41,42,43]. 
 
Buprenorphine  
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Buprenorphine is an emerging therapy for control of acute adult opioid withdrawal 
symptoms and medically assisted opioid replacement therapies. It has a long half-life, which 
allows once a day dosing. It is a partial  opioid agonist, which accounts for an excellent safety 
profile relative to the full agonist methadone. Buprenorphine has been investigated as a primary 
opioid for the pharmacologic treatment of NAS. Phase 1 studies investigated safety, dose finding, 
and initial proof of concept [44,45]. These investigations were followed by a blinded, randomized 
controlled trial comparing sublingual buprenorphine to oral morphine in 63 infants (the BBORN 
trial). Buprenorphine had a   shorter median length of treatment (15 vs. 28 days) and length of stay 
(21 vs. 33 days) (both p<0.0001) [46]. Safety and need for adjunctive phenobarbital treatment was 
similar in both groups. This therapeutic advantage was comparable to the phase 1 program (~35% 
decreased length of treatment compared to morphine).  In all these trials, the in utero exposure of 
the infants was largely methadone. External validity of these single site, prospective trials is 
provided by retrospective cohort data from 212 infants in the southern Ohio region. Infants treated 
buprenorphine demonstrated a ~30% reduction in length of treatment compared to morphine and 
methadone controls [47,48]. This was multicenter and infants had a more heterogeneous in utero 
exposure of opioids and other drugs of abuse. The Ohio cohort employed the same buprenorphine 
formulation, but did use a different treatment regimen (summarized in [49]).  
Buprenorphine is administered sublingually in volumes of 0.5 mL or less, after which a pacifier is 
inserted in the mouth and absorption likely complete within 2 minutes. The current ethanol 
containing formulation is stable for 30 days in glass at room temperature and at least 7 days in 
polypropylene-dispensing syringes [50]. The ethanol provides asepsis and stability of the solution, 
and may promote absorption (though this has not been formally tested). Questions about the safety 
of the ethanol content has been raised [51]. The ethanol exposure seen in infants in the BBORN 
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trial were all lower than 7 mg/dL. The American Academy of Pediatrics guidance suggests a peak 
concentration of less than 25 mg/dL after administration of an ethanol containing medication [52] 
 
Non-opioid Adjunct Therapy 
The two agents used as adjuncts are the centrally acting alpha 2 adrenergic agonist 
clonidine and the GABA agonist phenobarbital. There have been a number of small studies which 
have compared an adjunct to an opioid. The ideal adjunct therapy or regimen has not been defined. 
The treatment approaches in which adjuncts are used are listed in Figure 3. In current use, adjuncts 
can be given only when symptoms are not controlled and weaned before cessation of the opioid. 
Other centers will wean the opioid first, and discontinue the adjunct later as an inpatient or 
outpatient. This approach is much more common for phenobarbital than clonidine. The third 
approach is that of parallel opioid and clonidine therapy, with a goal of reducing opioid exposure 
was well as length of treatment.   
 
Clonidine 
Clonidine has inhibitory effects on the release of noradrenaline which leads to a decrease 
in withdrawal symptoms [53]. In adults it is used for reduction of acute opioid withdrawal 
symptoms, but not chronic management of opioid use disorder. The highest quality evidence of 
efficacy in NAS is that of a randomized controlled trial of Agthe et al (n= 80). Clonidine added to 
the standard opioid treatment reduced diluted tincture of opium/kg per day compared to the 
placebo (p<0.03) and improved median length of therapy compared to placebo (11 vs 15 days, P 
= 0.02) [54]. Twelve percent of the infants in the placebo group had treatment failure while there 
were none in the clonidine group. A second unblinded RCT (n=68) by Surran that was stopped 
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early compared clonidine to phenobarbital on a base of morphine treatment. Phenobarbital had 
18.2 and clonidine 13.6 days of opioid treatment (p= 0.037) [55]. Clonidine was stopped before 
discharge while infants were sent home on phenobarbital, often for months. The doses of both 
adjuncts were also high. A prospective pilot study of Bada (n= 31) compared clonidine vs. 
morphine as primary treatment. Clonidine has shorter median length of treatment (28 compared to 
39 days). Though there were early differences in NICU Network Neurobehavioral Scale (NNNS) 
summary scores, at one year cognitive, motor and language scores did not differ between the 
groups [56] In adults, clonidine has less sedation than phenobarbital, but is subject to rebound 
hypertension with rapid cessation. In the inpatient setting, the side effect profile of clonidine has 
been reassuring.    
 
Phenobarbital  
Phenobarbital is a drug widely used for the treatment of non-opioid NAS, as well as 
commonly used in the NICU as an antiepileptic. Most common use is as an adjunct to an opioid. 
While described as and effective alternative to an opioid as base therapy, [57] the overwhelming 
current use is that as adjunct to an opioid when symptoms become severe. At what point 
phenobarbital is added is more variable between sites than that seen with clonidine. A common 
approach is to add when the maximal dose of the opioid is reached. Another approach is to add 
early, when the velocity of symptom change will suggest more severe NAS presentation [58]. In a 
partially randomized study of 20 infants, Coyle described decreased mean lengths of stay 79 vs 38 
days when phenobarbital was added to diluted tincture of opium (p <0.001) [59]. The long length 
of stay from this 2002 and likely different modes of non-pharmacologic treatment at the time make 
direct comparisons to current care less clear. However, the general vector of decreased opioid use 
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with addition of phenobarbital is clear. A concern limited more widespread use of phenobarbital 
early on is that of safety and long term neurodevelopment. The product label states use has been 
associated with cognitive deficits in children taking for seizures, and animal models of long term 
behavioral outcome are also of potential concern [60]. The issue of potential bias by indication for 
a seizure population makes direct comparisons to infants with NAS difficult. Long term 
neurodevelopmental outcome studies of infants treated for NAS are subject to occult bias due to 
the in utero opioid exposure, opioid used to treat NAS, and most importantly the environment the 
infant is raised in which make comparisons to non-phenobarbital exposed controls problematic. 
The widespread use of phenobarbital in the NICU, familiarity of clinicians with use, and lack of 
clear evidence of toxicity have led to continued use as an adjunct in NAS. Whereas clonidine has 
a mechanism of action more specific to opioid withdrawal, phenobarbital has a more global 
sedative effect which may provide added efficacy in circumstances of poly-substance exposure. 
 
Treatment Location 
Pharmacologic treatment is most commonly administered in the inpatient setting. There 
have been a number of sites that transition pharmacologic treatment to the outpatient setting. 
Opioids, particularly the long acting agent methadone, has been used in the outpatient setting. 
More commonly, the opioid is weaned during the inpatient stay or soon after discharge with 
phenobarbital being the primary pharmacologic therapy. Any attempt to transition treatment to the 
outpatient setting requires a robust follow up mechanism and outpatient pediatricians familiar and 
comfortable with managing an outpatient wean. Compared to outpatient weaning, the use of 
inpatient pharmacologic treatment is consistently reported as being associated with longer lengths 
of hospitalization, but shorter total duration of treatment [61]. The best documented experience is 
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a population based retrospective cohort study of 532 infants reported infants. Consistent with prior 
studies, the median (IQR) length of pharmacological therapy was significant shorter in inpatients 
compared to outpatients 19 (10-31) days vs. 60 (38-92) days; p<0.001) [62]. Infants treated as 
outpatients had have an increased number of emergency room visits within 6 months of discharge 
(adjusted odds ratio 1.52, 95% CI 1.06-2.17) when compared with those treated as inpatients alone 
[62]. While not statistically significant, the point estimate odd ratio for emergency visit at 6 weeks, 
or any hospitalization at 6 or 24 weeks was ~1.5 for outpatient compared to inpatient treatment. 
Most (82%) were treated with phenobarbital alone. These data suggest caution when considering 
transition to outpatient treatment, and only in circumstances where there is a comprehensive 
support structure to safely manage these infants. 
  
Discussion  
Non-Pharmacological treatment is the base therapy that should be administered to all 
infants with in utero exposure to opioids. Non-pharmacological treatments are safe, effective, and 
can be easy implemented. Interventions will vary by the ability of a site provide based upon 
physical layout, structure of maternal treatment, and staffing considerations. There has been 
examination of the relative merit of each specific element, but the evidence base upon which to 
evaluate interventions remains low. The issue is not one of safety, but instead from a menu of 
many non-pharmacologic interventions, infants and institutions will be best served if high impact 
interventions are chosen over lower. Future needs include standardized descriptions of 
interventions and comparative evaluation between them. Given the large matrix of possible 
combinations, a reasonable approach is to instead focus on comparisons of bundles with 
differentiation focused on high resource intensive activities. These would not necessarily need to 
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be randomized controlled trials but could be quality improvement initiatives or pragmatic 
investigations built into standard of care using electronic medical records.  
Pharmacological intervention is a cornerstone in achieving growth and symptom control in 
severe NAS. Recent years have seen the emergence of high quality evidence to refine choices. The 
choice of a specific agent is important, but not the only predictor of success. The treatment regimen 
within which the drug resides is a key consideration. Weight vs. symptom based dosing is just one 
area that would benefit from investigation. Newer modeling tools such a pharmacometrics hold 
promise in optimizing dose selection. A pharmacokinetic/pharmacodynamic model does not 
guarantee to identify the ideal dose, but it is significantly more likely to do so than the old method 
of intuition or hunch-based empiric regimen creation. Pharmacogenetic differences and disease 
expression and response to treatment may be helpful eventually, but this tool for NAS remains in 
the discovery phase and far from providing actionable decisions. The use of an opioid as primary 
therapy is settled practice. What agent, doses, titration schema, as well and when to start an adjunct, 
which one, and how to wean all are areas under current investigation. 
 
Practice points 
• Non-pharmacological treatments are safe, effective, and can be easy implemented. 
• Interventions will vary by the ability of a site provide based upon physical layout, structure of 
maternal treatment, and staffing considerations.  
• The need for pharmacologic therapy is widely held to be needed for severe symptomatology.  
• This is commonly linked to a specific threshold on a score (often an 8 on a Finnegan score) 
and less often explicitly linked to a goal of therapy.  
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• There is good consensus that there is a subset of infants that require pharmacologic therapy, 
but less so in defining the goals of care and tradeoffs associated with higher or lower threshold 
for treatment.  
• Goals of pharmacologic therapy are to relieve infant discomfort, allow proper nutrition and 
development, and to foster parental bonding. 
 
Research agenda  
• Future studies of non-pharmacological intervention should include standardized descriptions 
of interventions and comparative evaluation between them. Furthermore, given the large 
matrix of possible combinations, a reasonable approach is to instead focus on comparisons of 
bundles with differentiation focused on high resource intensive activities.  
• Future studies of pharmacological intervention should examine what agent, doses, titration 
schema, as well and when to start an adjunct, which one, and how to wean. In addition, long-
term outcomes should be addressed in any future studies.  
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Figure 1: Representative Modified Finnegan Score (MOTHER NAS score) 
 
Signs and Symptoms Severity  Score  
Crying Excessive high pitched  
Continuous high pitched  
2  
3  
Sleeps < 1 hours after feeding  
< 2 hours after feeding  
< 3 hours after feeding  
3  
2  
1  
Moro Reflex Hyperactive  
Markedly Hyperactive 
1  
2  
Tremors: Disturbed Hands or feet only, up to 3 seconds 
Arms or legs, over 3 seconds 
1  
2  
Tremors: Undisturbed Hands or feet only, up to 3 seconds 
Arms or legs, over 3 seconds 
1  
2  
Increased Muscle Tone  Difficult but possible to straighten arm and head 
lag present 
1 
Unable to straighten arm and head lag absent 2 
Excoriation  Skin is red but intact or healing 1 
Skin not intact 2 
Generalized Seizure  8  
Fever > 37.3 C (99.2 F)   1  
Frequent Yawning >4 or more successive times 1  
Sweating   1  
Nasal Stuffiness   1  
Sneezing (4 or more successive times)  >4 or more successive times 1  
Tachypnea  Respiratory Rate >60/mm 2  
Poor feeding   2  
Vomiting (or regurgitation)   2  
Loose Stools  Diaper is > half liquid/half solid 2 
Failure to thrive  Current weight > 10% below birth weight 2  
Excessive Irritability  Consoling calms infant in <5 min 1 
 Consoling calms infant in 6-15 min 2 
 Inconsolable  3 
 Summed Score  
Recorded, unscored elements 
Convulsions 
Fever > 38.4 C (101.2 F) 
Mottling 
Excessive sucking 
Watery Stools 
Projectile vomiting 
Retractions 
Nasal flaring 
Myoclonic jerks 
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Figure 2: Approach to infants with in utero opioid exposure. All infants should be provided a base of non-pharmacologic therapies. 
Specific measures will vary with the ability of the local site to provide. Some potential approaches are listed. Pharmacologic therapy is 
added only in those for whom symptoms are not controlled with non-pharmacologic means. 
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Figure 3: Role of Adjunctive Therapies. The optimal use of adjunctive therapy with an opioid has not been defined. (A) An adjunct is 
used only when symptoms are severe and the adjunct is weaned before the opioid. (B) The adjunct is started in those not controlled 
with an opioid, but the adjunct is continued after the opioid is weaned, sometimes in an outpatient setting. (C) The adjunct serves as an 
opioid sparing agent which is started and stopped at the same time as the opioid. 
 
 
 
 
 
 
 
  
A 
B 
C 
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Figure 4: NAS Treatment Flowchart at the Royal Alexandra Hospital, Edmonton, Canada 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
Confirmed or suspected maternal opioid use during pregnancy 
Scores consistently less than 8 are managed by 
supportive measures 
Bedside nurse to begin NAS scoring every 4 hours and adjust frequency as directed by site specific scoring tool 
Prescriber to initiate pharmacologic therapy additionally to 
supportive measures:  
-  3 consecutive scores of 8 or greater 
- Average of 3 consecutive scores is 8 or greater 
- Average of 2 consecutive scores of 12 or greater 
 
INITIATION PHASE: Start oral morphine 50 ug/kg/dose q3H and continue NAS scoring 
Newborn has been on morphine for 12 hours and 
continues to have 2 or more consecutive scores greater 
than or equal to 8  
  
WEANING PHASE:  
Once stabilized on same dose for 48 hours, use this dose as starting point of wean. 
Wean the dose by 10% of the total daily amount of the stabilization dose. Do not make dose changes more frequently than every 
24-72 hours as tolerated. 
If newborn is on morphine and an adjunct, wean off morphine first.  
ESCALATION PHASE:  
Increase dose by 15 mcg/kg/dose at 6 hour intervals until scores less 
than 8. Keep dose frequency q3H. 
NOTE: If morphine total daily dose is greater than 1000 ug/kg/day and 
scores remain over 8 consider adding an adjunctive treatment (A2) 
 
 
 
  
STABILIZATION PHASE: All scores remain 
less than 8 for 48 hours while on morphine 
therapy  
  
Discontinue morphine when scores are less than 8 
at 20 ug/kg/dose. Continue NAS scoring for 48 
hours after discontinuation.  
If newborn has 2 consecutive scores greater than 8, go back to previous 
dose at which newborn was stable. If unable to keep scores less than 8 
despite changing to previous dose, go back to escalation phase.    
If scores consistently less than 8, continue to 
decrease dose by 10% of the total daily amount of 
the stabilization dose.  Consider extending dosing 
interval to every 4 hours depending on newborn’s 
feeding schedule.  
Newborn requires oral morphine for discharge (weaning will happen as 
an outpatient). 
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Table 1: Methadone vs. Morphine: Studies in which morphine and methadone were compared for 
median length of treatment. 
 
Author 
 
Design N Morphine Methadone P 
Lainwala [64] 2005 Retrospective 46 36 40 >0.05 
Hall [40] 2014 Retrospective 383 16* 16* NS 
Young [65] 2015 Retrospective 26 7* 38* 0.001 
Brown [63] 2015 Blinded RCT 31 21 14 0.008 
Davis [39] 2018 Blinded RCT 183 15 11.5 0.02 
*= mean, RCT = randomized controlled trial 
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Box 1: Non Pharmacological Adjunct Treatments for Neonatal Abstinence Syndrome  
Non Pharmacological Adjunct Treatments  
Environmental control 
• Room lighting  
• Swaddling 
• Positioning 
• Bed types 
Feeding methods 
• Breastfeeding 
• Formula feeding 
Social Integration 
• Parental rooming in  
• Skin to Skin contact  
Treatment Location  
• Inpatient vs Outpatient 
Acupuncture 
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Box 2: Pharmacological Treatments for Neonatal Abstinence Syndrome 
 
 
 
  
Pharmacological Treatments for NAS 
Opioid 
• Morphine  
• Methadone 
• Buprenorphine 
Non-opioid Adjunct Therapy 
• Clonidine 
• Phenobarbital 
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